NSE ScannerMedical Devices & Supplies · Medical Distributors · NSE: MONOPHARMA · data 2026-10-30
Mono Pharmacare Limited
In plain words
Price: 58.3% below its 52-week high of ₹22.05.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹166 cr |
| Net profit (last 12 months) | ₹0 cr |
| Sales growth, 3 years (yearly) | 83.1% |
| Profit growth, 3 years (yearly) | 1.5% |
At a glance
P/E 46.1, P/B 0.5, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 2.3%, ROCE 7.6%, operating margin 2.3%: how much profit it earns on the money it uses.
Debt/equity 1.77, Profit growth 1.5% and sales growth 83.1% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- High borrowing: debt/equity 1.77.
- Low return on equity (2.3%).
- Thin operating margin (2.3%).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Mono Pharmacare Limited debt-free?
Its latest reported debt-to-equity ratio is 1.77, meaning borrowings are larger than shareholders' equity.
What is Mono Pharmacare Limited's P/E ratio?
About 46.1, based on the last 12 months' earnings and a price of ₹9.2 (data 2026-10-30).
What is the 52-week high and low of Mono Pharmacare Limited?
The 52-week high is ₹22.05 and the 52-week low is ₹7.5.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Mono Pharmacare Limited | ₹9.2 | ₹16 cr | 46.1 | 0.5 | 2.3% | 7.6% | 1.77 | -53.2% |
| QMS Medical Allied Services Limited | ₹181.17 | ₹350 cr | 31.6 | — | 10.5% | 18.9% | 0.71 | +66.3% |
| Vijaypd Ceutical Limited | ₹76.05 | ₹149 cr | 29.6 | 2.8 | 11.8% | 9.2% | 0.7 | +70.9% |
| Balaxi Pharmaceuticals Limited | ₹19.15 | ₹106 cr | — | — | 0.6% | — | 0.23 | -55.3% |
| Aakaar Medical Technologies Limited | ₹71 | ₹101 cr | 15.2 | 1.8 | 17.1% | 25.8% | 0.34 | -15.5% |
| Vivo Bio Tech Ltd. | ₹13.72 | ₹31 cr | — | — | -2% | 8.3% | 0.72 | -31.9% |
Compare MONOPHARMA with QMSMEDI in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open MONOPHARMA in NSE Scanner →